<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIM: GLP-1(7-36)<z:chebi fb="0" ids="29337,32988">amide</z:chebi> (GLP-1) is an intestinal hormone with effects on <z:chebi fb="105" ids="17234">glucose</z:chebi> metabolism and feeding behavior, including insulinotropic, insulinomimetic, glucagonostatic and anorectic actions </plain></SENT>
<SENT sid="1" pm="."><plain>In experimental settings, GLP-1 has also been shown to diminish <z:mpath ids='MPATH_124'>infarct</z:mpath> size following heart <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>-reperfusion </plain></SENT>
<SENT sid="2" pm="."><plain>GLP-1 analogs with extended half-lives are continuously being developed against type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>Of these, only exendin-4 (exenatide, registered as Byetta) has been shown to mimic the <z:mpath ids='MPATH_124'>infarct</z:mpath> size-limiting effect of GLP-1 in a clinically relevant application as a postconditioning agent </plain></SENT>
<SENT sid="4" pm="."><plain>The aim of this work was to test, in a postconditioning mode, a novel, proteolysis-resistant GLP-1 analog N-Ac-GLP-1(7-34)<z:chebi fb="0" ids="29337,32988">amide</z:chebi>, herein termed curaglutide, for its cardioprotective ability </plain></SENT>
<SENT sid="5" pm="."><plain>METHOD: Global <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> (35 min)-reperfusion (120 min) was applied in isolated, retrogradely perfused rat hearts </plain></SENT>
<SENT sid="6" pm="."><plain><z:chebi fb="7" ids="16670">Peptides</z:chebi> were present for 15 min at the <z:hpo ids='HP_0003674'>onset</z:hpo> of reperfusion </plain></SENT>
<SENT sid="7" pm="."><plain>Cardiac function parameters (beats per minute, left ventricle developed and diastolic pressures, rate-pressure product) were measured </plain></SENT>
<SENT sid="8" pm="."><plain><z:mpath ids='MPATH_124'>Infarct</z:mpath> size was determined by 2,3,5-tripehyltetrazolium <z:chebi fb="76" ids="17996">chloride</z:chebi> staining and planimetry </plain></SENT>
<SENT sid="9" pm="."><plain>RESULTS: Curaglutide did not affect any of the functional heart parameters when administered without preceding <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="10" pm="."><plain>Curaglutide 0.3 nM diminished significantly the postischemic hypercontracture, with no significant effect on the left ventricle developed pressure or rate-pressure product </plain></SENT>
<SENT sid="11" pm="."><plain><z:mpath ids='MPATH_124'>Infarct</z:mpath> size was reduced by curaglutide postconditioning from 24.8% (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SEM</z:e> 2.8, N=14) to 11.4% (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SEM</z:e> 3.2, N=8; P&lt;0.05) </plain></SENT>
<SENT sid="12" pm="."><plain>These effects of curaglutide on postischemic hypercontracture and <z:mpath ids='MPATH_124'>infarct</z:mpath> size were similar in magnitude to corresponding effects of GLP-1 receptor <z:chebi fb="4" ids="48705">agonist</z:chebi> exendin-4 </plain></SENT>
<SENT sid="13" pm="."><plain>The cardioprotective effects of both agents were abolished in the presence of a GLP-1 receptor <z:chebi fb="68" ids="48706">antagonist</z:chebi> exendin(9-39) </plain></SENT>
<SENT sid="14" pm="."><plain>CONCLUSION: Curaglutide is a new, proteolysis-resistant GLP-1 analog with a beneficial effect on reperfusion-injury in an isolated rat heart </plain></SENT>
<SENT sid="15" pm="."><plain>Curaglutide was here shown to act through GLP-1 receptors </plain></SENT>
<SENT sid="16" pm="."><plain>Based on the present results, more extensive experimental studies in vivo, comparing dose-response characteristics and efficacy of curaglutide and exendin-4 appear warranted </plain></SENT>
</text></document>